---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-22-000102"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:36:17.210563+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Xeris Biopharma Q2 net product revenue record $25.3M, reaffirms FY guidance

## Summary
- Record Q2 net product revenue $25.3M, up 15% from Q1 and 34% pro forma YoY.
- Gvoke net revenue $11.5M (+30% YoY); Keveyis $12.8M (+28% pro forma); Recorlev $1.0M.
- Cash $111.6M at quarter-end; reaffirms FY net product revenue $105M-$120M, cash flow breakeven by end 2023.
- Net loss $26.2M ($0.19/sh) in Q2, $59.9M ($0.44/sh) in H1.
- Ogluo commercial partner Tetris Pharma acquired by Arecor Therapeutics in August 2022.

## SEC filing metadata
- accession: 0001867096-22-000102
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709622000102/0001867096-22-000102-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709622000102/xers-20220810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-22-000102
- JSON: https://secwatch.observer/filing/0001867096-22-000102.json
- Plain text: https://secwatch.observer/filing/0001867096-22-000102.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.